Publications

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

 156
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Tags:

Previous Article

Oncogene mutation in colorectal cancer leads to metabolic reprogramming

Next Article

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Related Posts

Targeting the peripheral neural-tumour microenvironment for cancer therapy

Targeting the peripheral neural-tumour microenvironment...

 152

Fam102a translocates Runx2 and Rbpjl to facilitate Osterix expression and bone formation

Fam102a translocates Runx2 and Rbpjl to facilitate Oste...

 137

Obesity-induced blood-brain barrier dysfunction: phenotypes and mechanisms

Obesity-induced blood-brain barrier dysfunction: phenot...

 184